Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
Recruiting now
Conditions studied: Colorectal Cancer
In brief
The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection. These CRC screening technologies would be low cost, breakthrough and of high sensitivity and specificity.
Key facts
- Study ID
- NCT06515821
- Run by
- Firalis SA
- People needed
- 4100
- Starts
- 2024-08-01
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2025-09-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- CRC Group
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥18 years
- Subject is willing to undergo FOBT test, colonoscopy, and tissue biopsy
- Subject for whom the decision to perform a colonoscopy has been made by the treating physician
- Subject has positive CRC diagnosis according to colonoscopy result
- Covered by a Health Insurance System
- Subject is able to comply with all study procedures
- Control Group with risks and presence of polyps
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥18 years
- Otherwise healthy individuals with recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidaemia.
- Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy
- Subject has negative CRC diagnosis according to colonoscopy result
- Covered by a Health Insurance System, which will cover colonoscopy as screening in patients with risk factors and alarm symptoms such as abdominal pain, change in stool texture, change in stool frequency, blood in stool/rectal bleeding, diarrhea, constipation, abdominal bloating, weight loss, tiredness.
- Control Group with risks and absence of polyps
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥18 years
- Otherwise healthy individuals with recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidaemia.
- Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy
- Subject has negative CRC diagnosis according to colonoscopy result
- Covered by a Health Insurance System, which will cover colonoscopy as screening in patients with risk factors and alarm symptoms such as abdominal pain, change in stool texture, change in stool frequency, blood in stool/rectal bleeding, diarrhea, constipation, abdominal bloating, weight loss, tiredness.
- Control Group with no risks
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥40 years
You may not qualify if…
- For the CRC Group
- Legal incapacity or limited legal capacity
- Subject did not sign the Informed Consent form
- Subject who, according to the investigator's assessment, presents with an unstable medical condition contraindicating the performance of the planned blood test, stool test or breath test
- Subject has had surgery in the previous 6-8 weeks or is under medication for CRC treatment.
- For the control groups
- Legal incapacity or limited legal capacity
- Subject did not sign the Informed Consent form
- Previous history of any type of cancer
- Gastrointestinal disorders or other serious acute or chronic diseases
Where it is running
- Military Medical Academy Sofia, Gastroenterology Clinic, 3 Sveti Georgi Sofiiski str., Sofia 1606, Bulgaria — Sofia, Bulgaria (enrolling)
- UMC Mainz: University Medical Center Mainz — Mainz-GE, Germany (enrolling)
- LSMU: Lithuanian University of Health Sciences Gastroenterology Department, — Kaunas, Lithuania (enrolling)
- IPO: Instituto Português de Oncologia — Porto, Portugal (enrolling)
- MKI UKSH Lübeck — Lübeck, Germany (enrolling)
- University Specialised Hospital for Active Treatment of Oncology Departement of Gastroenterology. — Sofia, Bulgaria
- UFC: Université de Franche-Comté Oncology department CHU Besançon — Besançon, France
- IBO: Institutul Oncologic Prof. Dr. Alexandru Trestioreanu București — Bucharest, Romania
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.